Annovis Bio, Inc.
ANVS
NYSE·Healthcare·Biotechnology·Mkt cap $59.1M
$1.39
▲ +0.72%
P/E
—
Mkt Cap
$59.1M
52-Wk Range
$1.32–$5.50
52-Week Range
$1.32 - $5.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 40.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary multi-target approach to protein degradation in neurodegenerative diseases
- Advanced clinical development stage with completed Phase 2a trials for multiple indications
- Diversified pipeline addressing multiple neurodegenerative conditions and patient populations
- Experienced management team in neurodegeneration drug development
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Phase 2b/3 clinical trial advancement for Buntanetap in Alzheimer's disease
Value
Valuation data unavailable
Momentum
Falling
-22.4% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying ANVS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 14, 2026
Reported EPS of -$0.40 vs -$0.45 consensus (+11.8% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.8%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Aug 27, 2026
vs Industry
How ANVS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related